Research Directions:
References:
1. Shih I-M and Kurman RJ Ovarian tumorigenesis- a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-8.
2. Singer G, Kurman RJ, Chang H-W, Cho SKR, and Shih I-M Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160: 1223-8.
3. Singer G, Oldt R, 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, and Shih Ie M Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-6.
4. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, and Shih IM Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation. Am J Surg Pathol 2005; 29: 218-24.
5. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, and Shih Ie M Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005; 65: 1994-2000.
6. Ho C-L, Kurman RJ, Dehari R, Wang T-L, and Shih I-M Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004; 64: 6915-8.
7. Chen Y-C, Pohl G, Wang T-L, Morin PJ, Risberg B, Kristensen G, Yu A, Davidson B, and Shih I-M Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 2005; 65: 331-7.
8. Hsu C-Y, Bristow R, Cha M, Wang BG, Ho C-L, Kurman RJ, Wang T-L, and Shih I-M Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004; 10: 6432-6.
9. Buckhaults P, Zhang Z, Chen YC, Wang TL, St Croix B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, and Shih Ie M Identifying tumor origin using a gene expression-based classification map. Cancer Res 2003; 63: 4144-9.
10. Singer G, Rebmann V, Y-C C, Liu H-T, Ali SZ, Reinsberg J, McMaster M, Pfeiffer K, Chan DW, Wardelmann E, Grosse-Wilde H, Kurman RJ, and Shih I-M HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003; 9: 4460-4.
11. Davidson B, Zhen Z, Kleiberg L, Li M, Forenes VA, Wang TL, and IM. S Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2006; in press (Oct 15 issue).
12. Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, Montz FJ, Roden R, Zhang Z, Chan DW, Kurman RJ, and Shih Ie M Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst 2002; 94: 1697-703.
13. Chang H-W, Ali SZ, Cho SKR, Kurman RJ, and Shih I-M Detection of allelic imbalance in ascitic supernatant by Digital SNP analysis. Clin Cancer Res 2002; 8: 2580-5.
14. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW, and Shih Ie M Increased plasma DNA integrity in cancer patients. Cancer Res 2003; 63: 3966-8.
15. Shih Ie M and Kurman RJ Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005; 11: 7273-9.
16. Chen YC, Davidson B, Cheng CC, Maitra A, Giuntoli RL, 2nd, Hruban RH, Wang TL, and Shih Ie M Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. Biochim Biophys Acta 2005; 1730: 96-102.
17. Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, and Shih Ie M HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 2005; 96: 42-7.
18. Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, and Shih Ie M Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006; 12: 827-31.
19. Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, and Wang TL Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A 2005; 102: 14004-9.
20. Davidson B, Trope CG, Wang TL, and Shih IM Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol 2006; PubMed on line.
21. Park JT, Li M, Nakayama N, Davidson B, Eberhart CG, Kurman RJ, Shih I-M, and Wang T-L. Notch-3 gene amplification in ovarian cancer. Cancer Res 2006; 66: 6312-8.
22. Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE, Shih Ie M, and Wang TL Homozygous Deletion of MKK4 in Ovarian Serous Carcinoma. Cancer Biol Ther 2006; 5: 630-4.
23. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu V, Wang TL, and Shih IM Sequence mutations and amplificatin of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 2006; 5: 779-85.
24. Nakayama K, Nakayma N, Davidson B, Sheu JJC, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL, and IM S A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci 2006; in press.
25. Shih IM, Torrance C, Sokoll LJ, Chan DW, Kinzler KW, and Vogelstein B Assessing tumors in living animals through measurement of urinary beta- human chorionic gonadotropin. Nat Med 2000; 6: 711-4.
26. Shih Ie M and Wang TL Apply innovative technologies to explore cancer genome. Curr Opin Oncol 2005; 17: 33-8.
|
